[2P-0578] IMiDs mediated growth suppression of hematological malignancies

〇Hidekatsu Iha¹, Emi Ikebe^1,2, Shunsuke Shimosaki³, Nichole Fife¹, Lindsay Fajardo¹, Mitsuo Hori⁴, Hiroo Hasegawa⁵, Naoki Hijiya⁶, Yoshiyuki Tsukamoto⁶, Masatsugu Moriyama⁶, Jiro Kikuchi⁷, Yusuke Furukawa⁷, Shotaro Hagiwara⁸, Masumichi Saito², Kazuhiro Morishita³ (1.Dept. Microbiol., Oita Univ. Facult. of Med., 2.Dept. Safety Res. Blood Biol. Products, Natl. Inst. Infect. Dis., 3.Tumor Cell Biochem., Dept. Med. Sci., Facult. Med., Univ. Miyazaki, 4.Dept. Hematol., Ibaraki Pref. Centl. Hosp., 5.Dept. Lab. Med., Nagasaki Univ. Grad. Sch. Biomed. Sci., 6.Dept. Mol. Pathol., Oita Univ. Facult. of Med., 7.Center Mol. Med., Jichi Med. Univ., 8.Dept. Hematol., Tokyo Women's Med. Univ.)

immunomodulatory drugs (IMiDs), adult T-cell lymphoma/leukemia (ATL), cereblon (CRBN)